Denise E. Hilling

Erasmus MC Cancer Institute

Papers

2

Total Citations

86

H-Index

2

About

Denise E. Hilling is a leading surgical oncologist whose research is transforming colorectal cancer care through rigorous clinical trials and a deep commitment to patient outcomes. Her primary research areas include minimally invasive surgery, intraoperative imaging, and long-term health-related quality of life (HRQoL) in rectal cancer. Dr. Hilling’s most impactful contribution is her leadership of the landmark AVOID trial (2024), a multicentre, randomised, phase 3 study that demonstrated how indocyanine green near-infrared fluorescence angiography can significantly reduce anastomotic leakage in minimally invasive colorectal surgery—a finding with immediate, life-saving implications for thousands of patients. This work has already garnered 84 citations and is reshaping intraoperative decision-making. She also investigates the long-term effects of surgical technique, as shown in her 2025 Dutch cohort study comparing robot-assisted versus conventional laparoscopic total mesorectal excision, which addresses a critical gap in understanding HRQoL beyond one year. By blending high-level evidence with patient-centered endpoints, Dr. Hilling exemplifies how rigorous surgical research can improve both survival and quality of life.

Research Focus

Key Achievements

2
H-Index
2
Papers
86
Total Citations
43
Avg Citations/Paper
🏆 Most Cited Paper
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial
84 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 38
🏛 Institutions: Erasmus MC Cancer Institute

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago